Nurix Therapeutics (NRIX) director awarded 31,250 stock options
Filing Impact
Filing Sentiment
Form Type
4
Rhea-AI Filing Summary
Nurix Therapeutics director Roy D. Baynes received a grant of 31,250 stock options to buy Nurix common stock. The options have an exercise price of $15.86 per share and expire on May 14, 2036, providing long-term equity-based compensation.
The award vests 100% on the earlier of the company’s next annual stockholder meeting or May 15, 2027, so long as Baynes continues to provide service through the vesting date. After this grant, he holds 31,250 derivative securities linked to Nurix common stock directly.
Positive
- None.
Negative
- None.
Insider Trade Summary
1 transaction reported
Mixed
1 txn
Insider
Baynes Roy D.
Role
null
| Type | Security | Shares | Price | Value |
|---|---|---|---|---|
| Grant/Award | Director Stock Option (right to buy) | 31,250 | $0.00 | -- |
Holdings After Transaction:
Director Stock Option (right to buy) — 31,250 shares (Direct, null)
Footnotes (1)
- [object Object]
Key Figures
Options granted: 31,250 options
Exercise price: $15.86 per share
Expiration date: May 14, 2036
+2 more
5 metrics
Options granted
31,250 options
Director stock option award to Roy D. Baynes
Exercise price
$15.86 per share
Exercise price of director stock options
Expiration date
May 14, 2036
Option term end for the grant
Vesting deadline
May 15, 2027
Latest possible full vesting date, subject to service
Total derivatives after grant
31,250 options
Total derivative securities held directly after transaction
Key Terms
Director Stock Option (right to buy), exercise price, expiration date, vests as to 100% of the award
4 terms
Director Stock Option (right to buy) financial
"security_title: Director Stock Option (right to buy)"
exercise price financial
"conversion_or_exercise_price: 15.8600"
The exercise price is the fixed amount at which you can buy or sell an asset, like a stock, when using an options contract. It matters because it helps determine whether exercising the option will be profitable or not, depending on the current market price. Think of it as the set price you agree on today to buy or sell later.
expiration date financial
"expiration_date: 2036-05-14T00:00:00.000Z"
The expiration date is the deadline after which a financial contract, such as an option or a futures agreement, is no longer valid or can be exercised. It matters to investors because it determines the timeframe during which they can take action or benefit from the contract, similar to how a coupon or a food item has a limited period of usefulness. Once the expiration date passes, the contract loses its value or ability to be used.
vests as to 100% of the award financial
"The stock option vests as to 100% of the award on the earlier"
FAQ
What insider transaction did Nurix Therapeutics (NRIX) report for Roy D. Baynes?
Nurix reported that director Roy D. Baynes received a grant of 31,250 stock options. These options are compensation-based awards, not an open-market share purchase, and give him the right to buy Nurix common stock at a fixed exercise price in the future.
How many stock options did Roy D. Baynes receive in this NRIX Form 4 filing?
Roy D. Baynes received 31,250 Director Stock Options in this transaction. Each option is a right to buy one share of Nurix common stock, aligning his compensation with shareholder interests through potential future stock price appreciation.
What is the exercise price and expiration date of the Nurix stock options granted to Baynes?
The options have an exercise price of $15.86 per share and expire on May 14, 2036. This means Baynes can choose to buy Nurix common stock at $15.86 any time before that expiration date, once the options are vested.
When do Roy D. Baynes’s Nurix director stock options vest?
The options vest 100% on the earlier of Nurix’s next annual stockholder meeting or May 15, 2027. Vesting is conditional on Baynes continuing to provide service to Nurix through the applicable vesting date specified in the award terms.